Prof. Inas Alhudiri is a clinician-scientist and national leader in cancer genomics and genetic research in Libya. With advanced clinical and academic training, she combines medical expertise with cutting-edge genomic science to advance precision medicine within the Libyan population.
She earned her Ph.D. from the University of Nottingham, United Kingdom, and holds a Bachelor of Medicine, Bachelor of Surgery (MB ChB) from Sabha University. She is also a Member of the Royal College of Surgeons of Glasgow (MRCS – Glasgow), reflecting her strong clinical foundation and international professional standing.
Prof. Inas serves as:
• Head of the Department of Genetic Engineering
• Director of the Libyan Biobanks Project
• Member of the Bioethics Committee.
She is contributing to major international collaborations including the assessing genomic diversity in African population (AGenDA Project) in collaboration with Witwatersrand University in South Africa.
She is deeply committed to academic mentorship and research capacity building. Prof. Inas supervises numerous Master’s and Ph.D. candidates and leads specialized workshops and national training initiatives in Genomics and Bioinformatics, strengthening the next generation of scientists and clinicians.
Based at the Libyan Biotechnology Research Center, Prof. Inas leads pioneering research in:
• Cancer genomics focusing on women’s health, with particular interest in breast and colorectal cancer
• Genomic diversity in health and disease within the Libyan population
• Translation of genomic discoveries into clinically meaningful applications
Her work contributes to advancing precision oncology and understanding population-specific genetic risk factors in North Africa.

1. Ramsay M, Etheredge H, Tluway F, D’Amato ME, Chikwambi Z, Hamdi Y, Alhudiri I et al. Enriching African genome representation through the AGenDA project. Nature. 2026 Jan;649(8097):565–73.
2. Alhudiri IM, Nolan CC, Ellis IO, et al. Expression of cathepsin D in early-stage breast cancer and its prognostic and predictive value. Cancer Research 2022 82: 5405–5405
3. Alhudiri I, Zaghdani AA, El Meshri SE, Elmaghrabi A, Elzagheid A. Libya floods: preventing a public health crisis. The Lancet 2023; 402: 1828–9.
4. Alhudiri I, Ebrahim F, Elzagheid A. Unregulated use of Artemisia in cancer patients in Libya: an emerging ethical and public health concern. Mansur A, Bakoush O, editors. Libyan Journal of Medicine. 2026 Jan 14;21(1):2611580.
5. Elmaihub ES, Alhudiri I, Ramadan AM, Eljilani M, Elzagheid A, Elfagi F, et al. Analysis of BRCA1 germline variants (exons 5, 11 and 20) in breast cancer families from Libya. Libyan J Med [Internet]. 2024 Dec 31 [cited 2024 Oct 27];19(1):2356906. Available from: https://www.tandfonline.com/doi/full/10.1080/19932820.2024.2356906
6. Elshwekh H, Alhudiri IM, Elzagheid A, Enattah N, Abbassi Y, Abou Assali L, et al. Assessing the Impact of Novel BRCA1 Exon 11 Variants on Pre-mRNA Splicing. Cells. 2024;13(10):824.